Pterostilbene, a natural compound structurally similar to resveratrol, has been studied for its potential effects on components of metabolic syndrome, including dyslipidemia, hyperglycemia, and insulin resistance. The scientific interest primarily stems from preclinical studies in animal models, where pterostilbene has demonstrated antioxidant, anti-inflammatory, and lipid-lowering properties. Some rodent studies report improved insulin sensitivity, lower blood glucose, and reductions in cholesterol and triglycerides following pterostilbene supplementation.

Human evidence, however, remains limited and of modest quality. A few small clinical trials, such as a 2012 double-blind, placebo-controlled study, have shown pterostilbene may reduce LDL cholesterol and blood pressure in adults with hypercholesterolemia, but effects on other metabolic syndrome parameters are inconsistent and sometimes modest. The safety profile appears acceptable at studied doses, but there is insufficient long-term data.

Overall, while there is preliminary scientific support from animal studies and early human trials, the evidence base is not robust. Larger, well-controlled clinical studies are needed to firmly establish efficacy and optimal dosing in metabolic syndrome. Therefore, pterostilbene’s use in this context is justified by early scientific evidence, but its clinical value is not yet clearly established.